Retraction: Novel approach to activity evaluation for release-active forms of anti-interferon-gamma antibodies based on enzyme-linked immunoassay (PLoS ONE (2017) 9: 5 (e97017) DOI: 10.1371/journal.pone.0097017);Novel approach to activity evaluation for release-active forms of anti-interferon-gamma antibodies based on enzyme-linked immunoassay

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Gavrilova, Elena S ^a   Bobrovnik, Sergey A ^b   Sherriff, Gordon ^c   Myslivets, Andrey A ^a   Tarasov, Sergey A ^a   Epstein, Oleg I ^a  

^a R and D Department   (Russian Federation)

^b PALLADIN INSTITUTE OF BIOCHEMISTRY   (Ukraine)

^c Ab Biotechnology Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; IFNG PROTEIN, HUMAN; IMMOBILIZED PROTEIN; MONOCLONAL ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MOLECULAR INTERACTION; CHEMISTRY; HUMAN; IMMUNOLOGY; PROCEDURES; SOLUBILITY;

ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMOBILIZED PROTEINS; INTERFERON-GAMMA; SOLUBILITY;

EID: 84901207706     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0197086     Document Type: Erratum

References (34)

1. Buss NAPS, Henderson SJ, McFarlane M, Shenton JM, de Haan L (2012) Monoclonal antibody therapeutics: history and future. Curr. Opin. Pharmacol, 12(5), 615. doi: 10.1016/j.coph.2012.08.001.
2. Frenzel A, Fröde D, Meyer T, Schirrmann T, Hust M (2012) Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display. Curr. Biotechnol. 1, 33-41. doi:10.2174/22111550111201010033
3. Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F (2005) Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources. ILAR J. 46(3), 258-268. doi:10.1093/ilar.46.3.258
4. Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM (2007) Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjugate Chem. 18(2), 447-55. doi:10.1021/bc060349x. (Pubitemid 46493516)
5. Cao M, Cao P, Yan H, Lu W, Ren F, et al. (2009) Construction, purification, and characterization of anti-BAFF scFv-Fc fusion antibody expressed in CHO/dhfr- cells. Appl Biochem Biotechnol. 157(3), 562-74. doi: 10.1007/s12010-008-8434-6.
6. Vanhove B, Laflamme G, Coulon F, Mougin M, Vusio P, et al. (2003) Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-a1-antitrypsin fusion antibody. Blood, 102(2), 564-570. doi:10.1182/blood-2002-08-2480. (Pubitemid 36841976)
7. Chames P, Van Regenmortel M, Weiss E, Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol, 157(2), 220-233. doi: 10.1111/j.1476-5381.2009.00190.x.
8. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov, 9, 325-338 doi:10.1038/nrd3003
9. Bailbé D, Philippe E, Gorbunov E, Tarasov S, Epstein O, et al. (2013) The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: comparison with rosiglitazone. J Diabetes Res. 2013, 763125. doi: 10.1155/2013/763125.
10. Dugina JL, Petrov VI, Babayeva AR, Martyushev-Poklad AV, Tcherevkova EV, et al. (2005) A randomized, open-label, comparative, 6-month trial of oral ultralow doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis. Int J Tissue React. 27(1), 15-21. (Pubitemid 40439615)
11. Epstein OI, Vorobeva T, Berchenko O, Garbuzova S, Geiko V, et al. (1996) Information and ontological models of adaptation. IMPE, Moscow.
12. Epstein OI (2009) Ultra-Low Doses (History of one research). Publishing Office of the Russian Academy of Medical Sciences, Moscow.
13. Epstein OI (2012) Release-activity: a long way from the phenomenon to new drugs. Bull Exp Biol Med. 154(1), 54-58. doi: 10.1007/s10517-012-1874-6.
14. Epstein OI (2013) Release activity phenomenon and spatial homeostasis hypothesis. Usp. Fiziol. Nauk. 44(3), 54-76 (in Russian).
15. Nicoll J, Gorbunov EA, Tarasov SA, Epstein OI (2013) Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro. Int J Endocrinol. 2013, 925874. doi:10.1155/2013/925874
16. Sakat SS, Mani K, Demidchenko YO, Gorbunov EA, Tarasov SA, et al. (2014) Release-active dilutions of diclofenac enhance anti-inflammatory effect of diclofenac in carrageenan-induced rat paw edema model. Inflammation,37(1), 1-9. doi: 10.1007/s10753-013-9705-0.
17. Tarasov SA, Zarubaev VV, Gorbunov EA (2012) Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A (H1N1) 2009 virus infection in mice. Antiviral Res. 93, 219-224. doi:10.1016/j.antiviral.2011.11. 018.
18. Vasil'ev AN, Sergeeva SA, Kachanova MV, Tarasov SA, Elfimova UV, et al. (2008) Use of ultralow doses of antibodies to gamma-interferon in the treatment and prophylaxis of viral infections. Antibiot Khimioter. 53, 32-35.
19. Aver'ianov AV, Babkin AP, Bart B, Volchetski AL, Minina ES, et al. (2012) Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial. Antibiot Khimioter. 57(7-8), 23-30 (in Russian).
20. Erman ES, Osidak LV, Sukhovetskaya VF, Drinevskii VP (2009) Efficiency of interferon inductor anaferon (pediatric formulation) in prophylaxis of acute respiratory infections in sickly children. Bull Exp Biol Med. 148(2), 270-4.
21. Shishkina LN, Sergeev AN, Kabanov AS, Skarnovich MO, Evtin NK, et al. (2008) Study of efficiency of therapeutic and preventive anaferon (pediatric formulation) in mice with influenza infection. Bull. Exp. Biol. Med. 146, 763-765. doi:10.1007/s10517-009-0378-5.
22. Shishkina LN, Skarnovich MO, Kabanov AS, Sergeev AA, Olkin SE, et al. (2010) Antiviral Activity of Anaferon (Pediatric Formulation) in Mice Infected with Pandemic Influenza Virus A (H1N1/09). Bull. Exp. Biol. Med. 149(5), 612-614. doi: 10.1007/s10517-010-1006-0.
23. Verevshchikov VK, Borzunov VM, Shemiakina EK (2011) Ergoferon and improvement of etiopathogenetic therapy of influenza and acute respiratore viral infection in adults. Antibiot Khimioter. 56(9-10), 23-6 (in Russian).
24. ICH harmonized tripartite guideline (2005) Validation of analytical procedures: text and methodology Q 2 (R1). Available: http://www.ich.org/. Accessed 2014 Apr 10.
25. Epstein OI, Sherstoboev EY, Martyushev-Poklad AV, Dugina YL, Sergeeva SA, et al. (2004) Dose-dependent effects and specificity of action of antibodies to endogenous regulators in ultralow doses. Bull Exp Biol Med. 137(5), 460-2. (Pubitemid 39158006)
26. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME (1985). Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods. 77, 305-319. doi: 10.1016/0022-1759(85)90044-4. (Pubitemid 15103678)
27. Stevens FJ (1987) A modification of an ELISA-based procedure for affinity determination: correction necessary for use with bivalent antibody. Molec. Immunol. 24. 1055-1060. doi: 10.1016/0161-5890(87)90073-3.
28. Bobrovnik SA (1998) Dynamics of the interaction of monoclonal antibodies with antigens immobilized on plates. Ukr. Biokhim. Zh. 70(3), 118-128 (in Russian).
29. Nygren H, Werthen M, Stenberg M (1987) Kinetics of antibody binding to solid-phase-immobilised antigen. Effect of diffusion rate limitation and steric interaction. J. Immunol. Methods. 101, 63-71. doi: 10.1016/0022-1759(87)90217-1. (Pubitemid 17097899)
30. Werthén M, Nygren H (1993) Cooperativity in the antibody binding to surface-adsorbed antigen. Biochim. Biophys. Acta. 1162. 326-32. doi:10.1016/0167-4838(93)90298-6. (Pubitemid 23094345)
31. Guggenheim EA (1926) XLVI. On the determination of the velocity constant of a unimolecular reaction. Philos Mag J Sci. 2(9), 538-543. doi:10.1080/14786442608564083.
32. Kezdy FJ, Jaz J, Bruylants A (1958) Cinétique de L'action de L'acide Nitreux sur les Amides I. Méthode Générale. Bull. Soc. Chem. Belg. 67(11-12), P.687-706. doi: 10.1002/bscb.19580671104.
33. Swinbourne ES (1960) Method for obtaining the rate coefficient and final concentration of a first-order reaction. J. Chem. Soc. 473, 2371-2372. doi:10.1039/JR9600002366.
34. Bobrovnik SA (1998) Determination of kinetic parameters for both reversible and irreversible first-order reaction. J. Biochem. Biophys. Methods. 37 (1-2), 53-68. PII: S0165-022X(98)00019-0.